The US FDA has designated NurOwn, developed by Israel’s Brainstorm, as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease).

http://jewishbusinessnews.com/2014/10/08/brainstorms-stem-cell-based-drug-nurown-gets-fda-fast-track-approval/